Dr. Feeha Nizami, Dr. Mansoor Ul Hassan, Dr. Asifa Tehreem
Alzheimer’s disease (AD) is the most common form of dementia accounting for 60–80% of dementia diagnosis and affects nearly 50 million people worldwide. The basic aim of the study is to find the therapeutic medicines used for the AD in Pakistani environment. This descriptive study was conducted at Allied Hospital, Faisalabad during March 2019 to December 2019. Basically we collect the data from doctors and patients both because we want to find the therapeutics of AD in local population of Pakistan. This study was completed almost in 3 months during 2017. We conduct the interviews and questionnaire for analysis. Measuring and, possibly, controlling space- and time-scaled adaptive and compensatory responses occurring during AD will represent a crucial step to achieve the capacity to substantially modify the disease course and progression at the best suitable timepoints, thus counteracting disrupting critical pathophysiological inputs. This approach will provide the conceptual basis for effective disease-modifying pathway-based targeted therapies. It is concluded that there are no clear and perfect medication for AD. The current diseased approach for AD consists of optimizing modifiable risk factors to reduce and delay symptom onset as well as symptomatic treatment after disease onset.